Kidney Disease Care Gets Precision Boost as Medical Journal Backs Combined Testing Approach

Chronic kidney disease patients could benefit from a more precise approach to monitoring their condition, according to guidance highlighted by the BMJ. The medical journal’s latest research suggests that combining routine estimation tools with reference measurements offers the most reliable strategy for long-term care.

The figures show that current practice relies heavily on estimated glomerular filtration rate (eGFR) calculations, which use blood creatinine levels to assess kidney function. NICE guidance recommends the CKD-EPI equation without ethnicity adjustment for eGFR calculation across the UK. But this convenient approach has limitations when precision matters most.

When Standard Tests Fall Short

Data suggests that combining creatinine with cystatin C – another blood marker – produces more accurate results than using either measurement alone. The KDIGO 2024 guidelines recommend this dual approach for confirmation in specific cases, chiefly when patients have muscle wasting or other conditions that might skew results.

For high-stakes decisions like chemotherapy dosing or kidney donor evaluation, measured GFR using reference standards such as 51Cr-EDTA provides the gold standard. This involves injecting a tracer substance and measuring how quickly the kidneys clear it from the blood.

Around 2.6 million healthy elderly people in the UK may be incorrectly flagged by traditional eGFR thresholds below 60 ml/min/1.73m². This could potentially exclude them from beneficial treatments, research indicates.

The Balancing Act

CKD staging relies on both eGFR and albumin-to-creatinine ratio measurements. Studies show that newer equations like CKD-EPI outperform older formulas such as MDRD in accuracy across different kidney function ranges.

The shift from race-based to race-free eGFR equations followed 2021 recommendations from American kidney foundations. Yet UK validation remains limited for the newest CKD-EPI 2021 formula, keeping the 2009 version as the standard.

Clinical experts increasingly favour the combined approach. Using both routine estimation and reference measurements when needed could reduce both under-diagnosis in complex cases and over-diagnosis in healthy elderly patients.

Practical Implementation

The strategy doesn’t mean abandoning current methods. Instead, it suggests using standard eGFR tests for routine monitoring as having reference measurements available when clinical decisions require absolute precision.

This balanced approach could prove chiefly valuable for patients whose kidney function sits near diagnostic thresholds or those with conditions that might affect standard test accuracy.

Key Takeaways

• Combining eGFR estimation with reference measurements provides more reliable kidney disease monitoring than either approach alone
• Standard blood tests remain suitable for routine monitoring, but precision measurements are advised for high-stakes clinical decisions
• Around 2.6 million healthy elderly Britons may be incorrectly diagnosed using current eGFR thresholds alone

What This Means for Kent Residents

Kent residents with chronic kidney disease receive care through NHS Kent and Medway Integrated Care Board, which uses NICE-recommended CKD-EPI calculations for routine monitoring in GP practices. Local renal units at trusts like East Kent Hospitals employ eGFR for screening but can arrange measured GFR tests when needed for transplant evaluation or precise drug dosing. Patients can access repeat eGFR testing through their GPs to track disease progression, and those with results near the 60 ml/min/1.73m² threshold should discuss with their doctor whether additional testing might provide clearer answers about their kidney health.